@DaveARicks
Account based inUnited States!
About this account
- Account based in
- United States
- Connected via
- United States App Store
X says this location may be affected by a proxy or VPN.
Account-level information from X, not a live location or the device used for a specific post.
Chair & CEO @EliLillyandCo. Building on 150 years of advancing human health by delivering breakthrough medicines and expanding access worldwide.
Indianapolis, Indiana
Joined November 2022
- Tweets22
- Following209
- Followers6.7K
- Likes39
In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.
Well I should have added a few more critical questions to this list
-Peer reviewed and presented at a medical meeting or published in a journal >>> pre print + press release while a meeting is going on
- For post hoc or RWE publish your methods and caveats, your sample and absolute event rates and measures - better to have it verified by independent group - real science is transparent and can be replicated.
EASD in 2 weeks! A lot of weight-loss numbers are about to drop..including 3 major studies from @EliLillyandCo.
Before we understand a molecule’s performance we need to understand design choices that move a topline weight loss number:
- Baseline & mix. BMI, diabetes status, sex and ethnicity all shift observed response
-Stats methods. Treatment-policy and efficacy estimands answer different questions and trial drop out matters for real world outcomes. Mixing them is not appropriate.
- Uncontrolled tails. Open-label extensions and crossovers can keep weight falling after randomization ends. That is not a new efficacy estimate.
- Execution. Lifestyle intensity, titration schedule, time at maintenance dose, and placebo-arm drop-in of approved medicines (important new trend..see ADA survo data).
Head-to-head data settle all this and should be much more widely used in the future. Where they don't exist, an indirect comparison is one data point — anchored, covariate-adjusted, prespecified, assumptions stated.
Those rules apply to our work too. Hold us to them.
Methods first. Then the number.
Obesity and its consequences is a global scourge.and 4 of 7 who suffer live in low and middle income countries. In the past we all expected it to take decades to reach these nations and people. Lilly has the medicines, the pipeline and the resources to make this better. Today we change the course- we will research, register, launch and partner to reach 10s of million more people.
Our goal: improve access to quality healthcare for 30M people living in resource-limited settings annually by 2030—and we’ve met it five years early. Today we launch Lilly Change the Course Commitment, aiming to bridge the gap in diabetes and obesity care in those areas. go.lilly.com/e6kbej
Dave A Ricks retweeted
In Milan, Italy, we're opening House of Lilly during #EASD2026. It brings art and science together to share our history, the inspiration behind our innovation and the science behind what comes next as we work to change the course of cardiometabolic health.
#WeAreLilly
Truth from my Euro colleagues. We are not HQ’d there but have massive operations in Europe. Unfortunately, short sighted policies are driving us all to the exit doors. When I joined this industry 30 years ago this was a European led industry, today Research, Clinical Development and Manufacturing are all shrinking in relative terms..Moving mostly to the US and increasing to China. The fix isn’t complicated but it is seemingly hard for them - improve IP, speed up the regulatory environment, value and pay for innovation - and the window is rapidly closing.⏱️
reuters.com/legal/litigation…
Thanks for making the trip down and big thanks to @GregAbbott_TX and his team for moving at $LLY speed. 4000 construction jobs, 600 new full time jobs, reshoring synthetic API to America 🇺🇸…and massive capacity for our weight loss pill for millions who need it around the world. A good day! @EliLillyandCo
Lilly CEO @DaveARicks tells me 700k new seniors have started on a GLP-1 medicine since Medicare coverage of obesity drugs launched on July 1.
He said Lilly is capturing about 70% of those new patients, and "a lot are still on Zepbound."
More from our exclusive interview soon!
EASD in 2 weeks! A lot of weight-loss numbers are about to drop..including 3 major studies from @EliLillyandCo.
Before we understand a molecule’s performance we need to understand design choices that move a topline weight loss number:
- Baseline & mix. BMI, diabetes status, sex and ethnicity all shift observed response
-Stats methods. Treatment-policy and efficacy estimands answer different questions and trial drop out matters for real world outcomes. Mixing them is not appropriate.
- Uncontrolled tails. Open-label extensions and crossovers can keep weight falling after randomization ends. That is not a new efficacy estimate.
- Execution. Lifestyle intensity, titration schedule, time at maintenance dose, and placebo-arm drop-in of approved medicines (important new trend..see ADA survo data).
Head-to-head data settle all this and should be much more widely used in the future. Where they don't exist, an indirect comparison is one data point — anchored, covariate-adjusted, prespecified, assumptions stated.
Those rules apply to our work too. Hold us to them.
Methods first. Then the number.
Millions of people live with diabetes and obesity, and the science keeps moving forward. This month, researchers and clinicians will gather in Milan for #EASD2026. We'll be there, sharing new findings as we work together to advance cardiometabolic health: go.lilly.com/fj92ce
This is the team that runs our medicine factory in Research Triangle Park, Lilly’s first new U.S. site in 40 years when announced. It makes the leading medicine for obesity and diabetes for millions of US patients.
Building it was harder than we thought: 3.5 years from announcement to first pack, six years to peak capacity. Pharma patent clocks and build clocks don't line up unless you design a platform - one that runs follow-on products and that the third, fourth, and fifth plants can reuse. We did.
Thank you, North Carolina state and local leaders, and a workforce that delivered. You set the template.
We're now building/built in Concord, Kenosha, Huntsville, Houston, Lebanon ( a town in Indiana!), Richmond, and the Lehigh Valley.
What still slows delivery: permit timelines and associated NIMBYisms, grid connections that aren't ready when the steel is, and big labor gaps in the building trades. The fixes are straightforward. Moving colleges and state, local, and federal agencies all at once is not.
Building is hard. Doing it in America is worth it.
#WeAreLilly
